158 related articles for article (PubMed ID: 22338033)
1. Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. I. Amrubicin accumulates to a lower level than doxorubicin or epirubicin.
Salvatorelli E; Menna P; Surapaneni S; Aukerman SL; Chello M; Covino E; Sung V; Minotti G
J Pharmacol Exp Ther; 2012 May; 341(2):464-73. PubMed ID: 22338033
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin.
Salvatorelli E; Menna P; Gonzalez Paz O; Surapaneni S; Aukerman SL; Chello M; Covino E; Sung V; Minotti G
J Pharmacol Exp Ther; 2012 May; 341(2):474-83. PubMed ID: 22338034
[TBL] [Abstract][Full Text] [Related]
3. Increased cellular accumulation and distribution of amrubicin contribute to its activity in anthracycline-resistant cancer cells.
Mamidipudi V; Shi T; Brady H; Surapaneni S; Chopra R; Aukerman SL; Heise C; Sung V
Cancer Chemother Pharmacol; 2012 Apr; 69(4):965-76. PubMed ID: 22120960
[TBL] [Abstract][Full Text] [Related]
4. Defective taxane stimulation of epirubicinol formation in the human heart: insight into the cardiac tolerability of epirubicin-taxane chemotherapies.
Salvatorelli E; Menna P; Gianni L; Minotti G
J Pharmacol Exp Ther; 2007 Feb; 320(2):790-800. PubMed ID: 17135345
[TBL] [Abstract][Full Text] [Related]
5. The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients.
Salvatorelli E; Menna P; Paz OG; Chello M; Covino E; Singer JW; Minotti G
J Pharmacol Exp Ther; 2013 Feb; 344(2):467-78. PubMed ID: 23192654
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicinolone formation and efflux: a salvage pathway against epirubicin accumulation in human heart.
Salvatorelli E; Menna P; Lusini M; Covino E; Minotti G
J Pharmacol Exp Ther; 2009 Apr; 329(1):175-84. PubMed ID: 19144686
[TBL] [Abstract][Full Text] [Related]
7. Effect of low-protein diet on anthracycline pharmacokinetics and cardiotoxicity.
El-Demerdash E; Ali AA; El-Taher DE; Hamada FM
J Pharm Pharmacol; 2012 Mar; 64(3):344-52. PubMed ID: 22309266
[TBL] [Abstract][Full Text] [Related]
8. Preclinical evaluation of the cardiotoxicity of taxane-anthracycline combinations using the model of isolated perfused rat heart.
Platel D; Pouna P; Bonoron-Adèle S; Robert J
Toxicol Appl Pharmacol; 2000 Mar; 163(2):135-40. PubMed ID: 10698671
[TBL] [Abstract][Full Text] [Related]
9. Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue.
Minotti G; Parlani M; Salvatorelli E; Menna P; Cipollone A; Animati F; Maggi CA; Manzini S
Br J Pharmacol; 2001 Nov; 134(6):1271-8. PubMed ID: 11704647
[TBL] [Abstract][Full Text] [Related]
10. Anthracyclines in the treatment of gynecologic malignancies.
Maluf FC; Spriggs D
Gynecol Oncol; 2002 Apr; 85(1):18-31. PubMed ID: 11925115
[TBL] [Abstract][Full Text] [Related]
11. Role of P-glycoprotein in accumulation and cytotoxicity of amrubicin and amrubicinol in MDR1 gene-transfected LLC-PK1 cells and human A549 lung adenocarcinoma cells.
Hira A; Watanabe H; Maeda Y; Yokoo K; Sanematsu E; Fujii J; Sasaki J; Hamada A; Saito H
Biochem Pharmacol; 2008 Feb; 75(4):973-80. PubMed ID: 18054347
[TBL] [Abstract][Full Text] [Related]
12. Low-Dose Anthracycline and Risk of Heart Failure in a Pharmacokinetic Model of Human Myocardium Exposure: Analog Specificity and Role of Secondary Alcohol Metabolites.
Salvatorelli E; Menna P; Chello M; Covino E; Minotti G
J Pharmacol Exp Ther; 2018 Feb; 364(2):323-331. PubMed ID: 29222131
[TBL] [Abstract][Full Text] [Related]
13. Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: predictiveness and pitfalls.
Robert J
Cell Biol Toxicol; 2007 Jan; 23(1):27-37. PubMed ID: 17041747
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacokinetics of new anthracyclines].
Robert J
Bull Cancer; 1988; 75(2):167-74. PubMed ID: 3282579
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic study on amrubicin and amrubicinol in Japanese patients with lung cancer.
Makino Y; Yamamoto N; Sato H; Ando R; Goto Y; Tanai C; Asahina H; Nokihara H; Sekine I; Kunitoh H; Ohe Y; Sugiyama E; Yokote N; Tamura T; Yamamoto H
Cancer Chemother Pharmacol; 2012 Apr; 69(4):861-9. PubMed ID: 22042514
[TBL] [Abstract][Full Text] [Related]
16. [Late phase II clinical study of amrubicin hydrochloride, a novel synthetic anthracycline derivative anticancer agent, for malignant lymphoma].
Akutsu M; Kano Y; Ogawa M; Miura A; Hirano M; Masaoka T; Tatsumi N
Gan To Kagaku Ryoho; 2001 Nov; 28(12):1867-76. PubMed ID: 11729479
[TBL] [Abstract][Full Text] [Related]
17. Drug-induced cardiotoxicity studied by longitudinal B-type natriuretic peptide assays and radionuclide ventriculography.
Pichon MF; Cvitkovic F; Hacene K; Delaunay J; Lokiec F; Collignon MA; Pecking AP
In Vivo; 2005; 19(3):567-76. PubMed ID: 15875778
[TBL] [Abstract][Full Text] [Related]
18. [Anthracycline-induced cardiotoxicity].
Petit T
Bull Cancer; 2004 Nov; 91 Suppl 3():159-65. PubMed ID: 15899623
[TBL] [Abstract][Full Text] [Related]
19. Exposure to anthracyclines during childhood causes cardiac injury.
Lipshultz SE
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacokinetic study of amrubicin in a case of small lung cancer on hemodialysis].
Ohsawa M; Demizu M; Chihara S; Ueda H; Igarashi T; Tomiyama N; Nakashima Y; Hosoi K; Min K
Gan To Kagaku Ryoho; 2009 Aug; 36(8):1311-4. PubMed ID: 19692770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]